BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10526879)

  • 1. Noncardiogenic pulmonary edema as the chief manifestation of a pheochromocytoma: a case report of MEN 2A with pedigree analysis of the RET proto-oncogene.
    Okada Y; Suchi M; Takeyama H; Hodgson ME; Kato T; Manabe T
    Tohoku J Exp Med; 1999 Jun; 188(2):177-87. PubMed ID: 10526879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
    Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
    Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence of pheochromocytoma in a MEN2A family with codon 609 mutation of the RET proto-oncogene.
    Igaz P; Patócs A; Rácz K; Klein I; Váradi A; Esik O
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2994. PubMed ID: 12050290
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple endocrine neoplasia type 2A with the identical somatic mutation in medullary thyroid carcinoma and pheochromocytoma without germline mutation at the corresponding site in the RET proto-oncogene.
    Akama H; Noshiro T; Kimura N; Shimizu K; Watanabe T; Shibukawa S; Nakai S; Miura W; Ito S; Miura Y
    Intern Med; 1999 Feb; 38(2):145-9. PubMed ID: 10225670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II.
    Neumann HP; Eng C; Mulligan LM; Glavac D; Zäuner I; Ponder BA; Crossey PA; Maher ER; Brauch H
    JAMA; 1995 Oct; 274(14):1149-51. PubMed ID: 7563486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
    Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
    Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
    Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
    Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
    J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel Val648Ile substitution in RET protooncogene observed in a Cys634Arg multiple endocrine neoplasia type 2A kindred presenting with an adrenocorticotropin-producing pheochromocytoma.
    Nunes AB; Ezabella MC; Pereira AC; Krieger JE; Toledo SP
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5658-61. PubMed ID: 12466368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene.
    Tessitore A; Sinisi AA; Pasquali D; Cardone M; Vitale D; Bellastella A; Colantuoni V
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3522-7. PubMed ID: 10522989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease.
    Caron P; Attié T; David D; Amiel J; Brousset F; Roger P; Munnich A; Lyonnet S
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2731-3. PubMed ID: 8675603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
    Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and clinical relevance of RET proto-oncogene germline mutations in pheochromocytoma patients.
    Januszewicz A; Neumann HP; Loń I; Szmigielski C; Symonides B; Kabat M; Apel TW; Wocial B; Lapiński M; Januszewicz W
    J Hypertens; 2000 Aug; 18(8):1019-23. PubMed ID: 10953992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
    Pausova Z; Soliman E; Amizuka N; Janicic N; Konrad EM; Arnold A; Goltzman D; Hendy GN
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A family of multiple endocrine neoplasia type 2A with the RET proto-oncogene mutation in codon 618 (Cys-->Arg).
    Nakao A; Naomoto Y; Kataoka M; Haisa M; Kataoka K; Saitoh S; Fujiwara T; Yamatsuji T; Shigemitsu K; Umeoka T; Isozaki H; Futami H; Yamaguchi K; Tanaka N
    Jpn J Clin Oncol; 2001 Apr; 31(4):157-61. PubMed ID: 11386462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of mutations in the MEN2A region of the ret proto-oncogene in non-MEN 2A phaeochromocytomas.
    Chew SL; Lavender P; Jain A; Weber A; Ross RJ; Wass JA; Besser GM; Clark AJ
    Clin Endocrinol (Oxf); 1995 Jan; 42(1):17-21. PubMed ID: 7889627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of mutations at codon 768 of the RET proto-oncogene in sporadic and hereditary pheochromocytomas.
    Yoshimoto K; Kimura T; Tanaka C; Moritani M; Iwahana H; Itakura M
    Endocr J; 1996 Feb; 43(1):109-14. PubMed ID: 8732460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.